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Abstract We prepared a specific antagonist for hepatocyte
growth factor (HGF) and designated it HGF/NK4. HGF/NK4 is
composed of N-terminal 447 amino acids of the K-chain of HGF,
thus contains the N-terminal hairpin domain and subsequent four
kringle domains. HGF/NK4 competitively inhibited the specific
binding of HGF to the receptor. Importantly, HGF/NK4 neither
stimulated DNA synthesis of primary cultured rat hepatocytes
(mitogenesis) nor induced cell scattering (motogenesis) and
branching tubulogenesis (morphogenesis) of MDCK renal
epithelial cells, however, HGF/NK4 almost completely inhibited
the mitogenic, motogenic, and morphogenic activities of HGF.
HGF/NK4 also suppressed tyrosine phosphorylation of the c-
Met/HGF receptor induced by HGF. Apparently this is the first
documentation of a specific antagonist which abrogates the
mitogenic, motogenic, and morphogenic activities of HGF.
z 1997 Federation of European Biochemical Societies.
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1. Introduction
Hepatocyte growth factor (HGF) was originally isolated
and cloned as a potent mitogen for mature hepatocytes [1^
6], but subsequent studies revealed that HGF is a pleiotrophic
factor which predominantly targets a wide variety of epithelial
and endothelial cells [7,8]. Several lines of studies revealed
multipotent features of HGF. Scatter factor was found to
be the same molecule as HGF [9], and HGF stimulates the
motility of various epithelial cells. HGF was also found to be
a ¢broblast-derived epithelial morphogen which induces
branching tubular morphogenesis [10]. HGF is expressed in
mesenchymal tissues, while c-Met/HGF receptor is expressed
in epithelial tissues during development of various organs [11].
Together with its mitogenic, motogenic (enhancement of cell
motility), and morphogenic activities, HGF has been consid-
ered to be a mediator in epithelial-mesenchymal interactions,
which supports organogenesis of various organs (reviewed in
[7,8]). In neoplastic tissues, HGF functions in tumor invasion
as a mediator in tumor-stromal interactions [12,13] and HGF
is likely to be one factor which stimulates neovascularization
in tumors [14,15]. Particular physiological functions of HGF
have been extensively studied as an organotrophic factor for
regeneration of various organs [7,8,16,17].
HGF is biosynthesized as a single-chain precursor of 728
amino acid residues and is proteolytically processed to a het-
erodimer molecule composed of a 69 kD K-chain and a 34 kD
L-chain [5]. The K-chain contains four kringle domains and
the L-chain the serine protease-like domain [5]. Studies on
structure-function relationships indicated that the N-terminal
hairpin loop, the ¢rst and second kringle domains of HGF are
essential for high-a⁄nity binding to the c-Met/HGF receptor
and thus essential for eliciting HGF activity [18^22]. Indeed,
HGF/NK2, a variant form of HGF composed of the N-ter-
minal hairpin domain and the ¢rst and second kringle do-
mains is produced by alternative splicing as a naturally occur-
ring variant [23,24]. Interestingly, HGF/NK2 can bind the c-
Met/HGF receptor and exert motogenic activity, but it has no
mitogenic activity, thus a small variant antagonizes the mito-
genic activity of HGF. On the other hand, the L-chain of
HGF alone fails to bind to the receptor, however the L-chain
seems essential for the mitogenic activity of HGF [18,21].
We have now prepared an antagonistic molecule for HGF
which we termed ‘HGF/NK4’. Notably, this HGF-antagonist,
HGF/NK4 antagonizes the mitogenic, motogenic, and mor-
phogenic activities of HGF. We describe herein the ¢rst report
on preparation of this HGF-antagonist.
2. Materials and methods
2.1. Materials
Human recombinant HGF was puri¢ed from the conditioned me-
dium of CHO cells transfected with human HGF cDNA [5,25]. The
purity of HGF exceeds 98%, as determined by SDS-PAGE and pro-
tein staining. Anti-phosphotyrosine monoclonal antibody (PY-20) was
obtained from Chemicon International, Inc. (Temecula, CA) and anti-
c-Met polyclonal antibody (C-12) from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA). Pyroglutamate aminopeptidase was obtained
from TAKARA Co. Ltd. (Otsu, Japan). Recombinant HGF/NK2 was
puri¢ed from the conditioned medium of COS-7 cells transfected with
cDNA corresponding to the sequence of human HGF/NK2, as de-
scribed elsewhere [22,23].
2.2. Preparation of HGF/NK4 and N-terminal amino acid sequencing
HGF was digested with pancreatic elastase (Sigma, St. Louis, MO)
in 0.2 M Tris/HCl bu¡er pH 8.8 for 20 min at 37‡C with an enzyme/
substrate ratio 1/100. The digested material was applied onto WBon-
dapack C4 reverse-phase HPLC column (Nihon Waters Ltd., Tokyo)
and eluted with a gradient of acetonitrile containing 0.05% tri£uoro-
acetic acid. Eluted fractions were evaporated by vacuum centrifuga-
tion and dissolved in 0.1 M phosphate bu¡er (pH 7.3) containing
0.05% CHAPS (Sigma) and 1 M NaCl. The N-terminal amino acid
sequence of the puri¢ed digested polypeptides was determined using
an automated protein sequencer model 492 (Applied Biosystem Inc.,
Foster City, CA).
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2.3. HGF receptor assay
Hepatic plasma membranes were prepared from adult rat livers and
HGF and HGF/NK4 were respectively radioiodinated by the chlor-
amine-T method, as described elsewhere [26]. The speci¢c activities of
125I-HGF and 125I-HGF/NK4 were 30^186 WCi/Wg protein. The bind-
ing assay was carried out by incubating 125I-HGF and 125I-HGF/NK4
with plasma membranes at 12‡C for 1 h, as described elsewhere [26].
The standard assay mixture contained various concentrations of 125I-
HGF and 125I-HGF/NK4, with or without 100 times excess molar
ratio of unlabeled HGF or HGF/NK4 and 50 Wg of plasma mem-
brane. All binding experiments were performed in quadruplicate. The
competitive binding assay was carried out by adding 60 pM 125I-HGF
and various concentrations of cold HGF or HGF/NK4, simultane-
ously, to rat plasma membranes.
2.4. Cell culture and assay for mitogenic activity in hepatocytes
MDCK clone 3B cells (a kind gift from Dr. R. Montesano) were
cultured in DMEM containing 10% FCS. For cell scattering assay,
MDCK cells were at a density of 1U104 cells/ml with or without
HGF and/or HGF/NK4, and the culture was run for 20 h. For
three-dimensional culture in collagen gels, MDCK cells were sus-
pended in ice-cold 0.2% collagen solution at a density of 104 cells/
ml. After the collagen solution gelled, culture medium containing
HGF and/or HGF/NK4 was added and cells were cultured for 6 h.
Mitogenic activity of HGF, HGF/NK4 and HGF/NK2 was deter-
mined by measuring DNA synthesis of adult rat hepatocytes in pri-
mary culture, as described elsewhere [5,18].
2.5. Detection of receptor tyrosine autophosphorylation
Subcon£uent A549 cells were cultured in serum-free DMEM sup-
plemented with 0.2% bovine serum albumin for 20 h. Serum-starved
cells were treated with HGF and/or HGF/NK4, and washed with PBS
containing 1 mM Na3VO4. Cells were frozen on dry-ice and scraped
o¡ in lysis bu¡er composed of 20 mM Tris/HCl (pH 7.4), 10 mM
EDTA, 150 mM NaCl, 2 mM Na3VO4, 5 Wg/ml leupeptin, 1 mM
phenylmethylsulfonyl £uoride, and 0.5% Triton X-100 and extracted
for 2 h at 4‡C. Tyrosine phosphorylation was detected following im-
munoprecipitation of c-Met/HGF receptor and subsequent Western
blotting, using an ECL enhanced chemiluminescence method (Amer-
sham, Little Chalfont, UK) as described elsewhere [18^20].
3. Results
3.1. Preparation and structural analysis of HGF/NK4
To generate an antagonistic molecule for HGF, highly pu-
ri¢ed recombinant HGF was digested with elastase and the
digested material was subjected to reverse-phase HPLC. The
elution pro¢le showed that the digested material separated to
three distinct peaks (Fig. 1A). SDS-PAGE and the following
protein staining indicated that a fragment of the ¢rst peak has
a Mr of 50 kD, under non-reducing conditions and 67 kD
under reducing conditions (Fig. 1B, HGF/NK4). Subsequent
analysis revealed that this fragment, designated as HGF/NK4
is an antagonistic molecule for HGF (see below). On the other
hand, the second peak corresponded to an undigested hetero-
dimeric HGF composed of 69 kD of K-chain and 34/32 kD L-
chain, in which the two distinct bands of L-chain were attrib-
uted to di¡erences in glycosylation. When the third peak was
subjected to SDS-PAGE, it showed 33/31 kD under non-re-
ducing conditions, and 34/32 kD under reducing conditions
(data not shown). Therefore, SDS-PAGE analysis suggested
that HGF was digested mainly into two fragments: the one
(HGF/NK4) is slightly smaller than the K-chain but has most
parts of the K-chain. The other fragment may be composed of
the entire L-chain and C-terminal small peptide of the K-
chain, in which these are linked by a disul¢de bridge, because
the cysteine residue involved in the disul¢de bridge to the L-
chain is 487Cys.
To determine the N-terminal amino acid sequence of HGF/
NK4, the puri¢ed material was subjected to N-terminal amino
acid sequence analysis, but this approach was unsuccessful
due to modi¢cation of the N-terminal amino acid. Since the
N-terminal amino acid of the HGF K-chain is pyroglutamate
[27], HGF/NK4 was treated with pyroglutamate aminopepti-
dase and then subjected to N-terminal amino acid sequencing.
The N-terminal amino acid sequence probed to be
RKRRNTIHEF which completely coincides with the 2nd to
11th N-terminal amino acids of the K-chain. Therefore, the N-
terminal amino acid of HGF/NK4 is glutamine modi¢ed to
pyroglutamate. Thus, the N-terminal structure of HGF/NK4
is the same as undigested HGF.
Next to determine the C-terminal end of HGF/NK4, we
analyzed N-terminal amino acid sequences of the remaining
fragment, assumed to be composed of the L-chain and the C-
terminal small peptide of the K-chain. In this case, we consid-
ered that the N-terminal amino acid analysis would produce
mixed sequences: one derived from the C-terminal small pep-
tide of the K-chain, and the other from the L-chain. As ex-
pected, N-terminal amino acid analysis of the other fragment
revealed paired amino acid residues: V/N, V/L, N/D, G/H, I/
P, P/V, T/I, R/S, T/-, N/A. The N-terminal amino acid se-
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Fig. 1. Elution pro¢le of HGF digested with elastase in C4 reverse-phase HPLC (A), analysis of polypeptide composition under SDS-PAGE
(B), and schematic structure of HGF/NK4 as determined by amino acid sequence analysis (C). Three distinct peaks separated by reverse-phase
HPLC were respectively subjected to SDS-PAGE under non-reducing or reducing conditions. Proteins were visualized by silver staining.
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quence of the L-chain is VVNGIPTRTN, therefore, the re-
mainder should be NLDHPVIS-A. This sequence corresponds
to 479Asn-488Ala. These results indicated that the C-terminal
end of HGF/NK4 is 478Val and that the remaining is com-
posed of the C-terminal 16 amino acids of the K- and L-chains
which are linked by a disul¢de bridge between 487Cys and
604Cys (Fig. 1C). Thus, HGF/NK4 is composed of a hairpin
domain and K1^K4 domains (Fig. 1C).
3.2. Receptor analysis
To determine if HGF/NK4 can bind to the cell surface
receptor, concentration-dependent binding of radiolabeled
HGF and HGF/NK4 was analyzed, using plasma membranes
prepared from rat liver (Fig. 2A, B). Scatchard analysis of
concentration-dependent binding of 125I-HGF up to 80 pM
resulted in a rectilinear plot (inset of Fig. 2A). The Kd value
and the number of HGF receptors were calculated to be 64.5
pM and 5478 sites/ng, respectively. Likewise, concentration-
dependent binding of HGF/NK4 and its Scatchard plot indi-
cated that the Kd value and the number of HGF/NK4 recep-
tors are 486 pM and 6427 sites/ng, respectively (Fig. 2B).
To determine if HGF/NK4 has the same binding site as
HGF, competitive binding analysis was carried out using
125I-HGF (Fig. 2C). Liver plasma membranes were incubated
in the presence of 125I-HGF alone, or 125I-HGF plus various
concentrations of cold HGF or HGF/NK4. Addition of cold
HGF competitively inhibited the speci¢c binding of 125I-HGF
to the plasma membrane, and 50% inhibition by cold HGF
was seen with 60 pM HGF: the dose approximately equimo-
lar to that of 125I-HGF. Likewise, addition of cold HGF/NK4
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Fig. 2. Concentration-dependent binding of radiolabeled HGF and HGF/NK4 to plasma membranes from rat liver (A, B), and replacement
curve of 125I-HGF binding to rat liver plasma membranes by unlabeled HGF or HGF/NK4 (C). Inset graphs in A and B show Scatchard plots
of each binding.
Fig. 3. Antagonistic e¡ect of HGF/NK4 on mitogenic activity of HGF. Mitogenic activity was determined by measuring DNA synthesis of rat
hepatocytes in primary culture. A: DNA synthesis of hepatocytes in the presence of HGF, HGF/NK4 or HGF/NK2. B: E¡ects of HGF/NK4
on DNA synthesis of hepatocytes in the presence of 60 pM HGF or 1.5 nM EGF.
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also inhibited the binding of 125I-HGF. Inhibitory e¡ects were
seen from 60 pM HGF/NK4 and HGF/NK4 almost com-
pletely inhibited the 125I-HGF binding at 60 nM; a 1000-
fold higher concentration than that of 125I-HGF. The inhib-
ition by 50% was seen with 600 pM HGF/NK4 and the con-
centration was 10-fold higher than that of HGF. Taken to-
gether, HGF/NK4 seems to competitively bind to c-Met/HGF
receptor with 8^10-fold lower a⁄nity than that of native
HGF.
3.3. Antagonizing activities of HGF/NK4
To address whether HGF/NK4 would abrogate biological
activities of HGF, we ¢rst examined the mitogenic activity of
HGF/NK4, using rat hepatocytes in primary culture (Fig. 3).
HGF dose-dependently stimulated DNA synthesis of hepato-
cytes (Fig. 3A), whereas HGF/NK4 as high as 100 nM had no
stimulatory e¡ect (Fig. 3A). Since HGF/NK2 is a competitive
inhibitor for binding of HGF to the receptor, we also exam-
ined whether HGF/NK2 has mitogenic and morphogenic ac-
tivities. HGF/NK2 as high as 10 nM had no stimulatory e¡ect
on DNA synthesis (Fig. 3A). Importantly, when HGF/NK4
was simultaneously added to cultures in the presence of HGF,
HGF/NK4 dose-dependently inhibited the DNA synthesis
stimulated by HGF, and almost completely inhibited at 60
nM, a 1000-fold higher concentration of HGF (Fig. 3B).
However, the inhibitory e¡ect of HGF/NK4 was not seen
when DNA synthesis was stimulated with epidermal growth
factor (EGF) (Fig. 3B). Thus, HGF/NK4 speci¢cally abro-
gates the mitogenic activity of HGF.
We next examined the biological activity of HGF/NK4,
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Fig. 4. Antagonistic e¡ect of HGF/NK4 on the motogenic activity of HGF. Motogenic activity was measured by evaluating cell scattering in
MDCK cells in monolayer culture. MDCK cells were cultured for 20 h in the absence (A) or presence of 22 pM HGF (B), 220 nM HGF/NK4
(C), 22 pM HGF plus 22 and 220 nM HGF/NK4 (D and E, respectively), or 220 pM HGF/NK2 (F).
Fig. 5. Antagonistic e¡ect of HGF/NK4 on morphogenic activity of HGF. Morphogenic activity was analyzed by evaluating the formation of
branching tubulogenesis in MDCK cells grown in a collagen gel matrix in the absence (A) or presence of 55 pM HGF (B), 55 nM HGF/NK4
(C), or 55 pM HGF plus 55 nM HGF/NK4 (D).
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using MDCK renal epithelial cells (Fig. 4). In control cultures,
MDCK cells formed tight colonies (Fig. 4A), whereas the
addition of 22 pM HGF enhanced the motility of MDCK
cells, and the MDCK cells scattered (Fig. 4B). In contrast,
HGF/NK4 did not induce any scattering of the cells, and the
cell-cell contact was well maintained (Fig. 4C). Moreover,
when HGF/NK4 was simultaneously added in the presence
of 22 pM HGF, HGF/NK4 inhibited scattering of the cells
as induced by HGF and maximal inhibition was seen with 22
nM HGF/NK4 (Fig. 4D and E). On the other hand, HGF/
NK2 at 220 pM induced cell scattering (Fig. 4F), which is
consistent with previous reports [18].
To determine if HGF/NK4 would antagonize the morpho-
genic activity of HGF, MDCK cells were grown in a collagen
gel matrix in the presence of HGF and/or HGF/NK4 (Fig. 5).
In control cultures without HGF, MDCK cells grew in the
form of spherical cysts (Fig. 5A). As previously noted, HGF
at 55 pM induced branching tubulogenesis in MDCK cells
(Fig. 5B), whereas HGF/NK4 as high as 55 nM, did not
induce branching tubulogenesis (Fig. 5C). HGF/NK4 com-
pletely abrogated the HGF-induced branching tubulogenesis,
and in this case MDCK cells grew as spherical cysts (Fig. 5D).
HGF/NK2 did not induce branching tubulogenesis (data not
shown).
Since HGF has growth inhibitory activity for several types
of tumor cells, we also examined whether HGF/NK4 would
antagonize the tumor inhibitory activity of HGF using
HepG2 human hepatoma cells. HGF inhibited proliferation
of HepG2 cells, whereas it was almost completely abrogated
by addition of HGF/NK4 (not shown). Thus, HGF/NK4 an-
tagonized the mitogenic, motogenic, morphogenic, and tumor
inhibitory activities of HGF.
3.4. Inhibition of the HGF-induced Met tyrosine
phosphorylation by HGF/NK4
We then asked whether the antagonistic e¡ect of HGF/NK4
on biological activities of HGF could be attributed to the
inhibition of tyrosine autophosphorylation of Met induced
by HGF. A549 cells were serum-starved and tyrosine phos-
phorylation of Met upon addition of HGF and/or HGF/NK4
was detected after immunoprecipitation and the following im-
munoblotting (Fig. 6). Addition of 110 pM HGF induced
tyrosine autophosphorylation of Met, however, the addition
of a higher concentration of HGF/NK4 (110 nM) scarcely
induced tyrosine phosphorylation of Met (Fig. 6). Simultane-
ous addition of HGF/NK4 dose-dependently inhibited tyro-
sine autophosphorylation of Met in the presence of HGF and
almost complete inhibition of this phosphorylation was seen
with 110 nM HGF/NK4 (Fig. 6). Therefore, HGF/NK4 sup-
pressed tyrosine phosphorylation of the c-Met/HGF receptor
and this inhibitory e¡ect is attributed to its antagonistic e¡ect
on the biological activities of HGF.
4. Discussion
Previous studies on the structure-function relationship in
HGF molecule revealed that the N-terminal hairpin domain,
the ¢rst kringle (K1), and the second kringle (K2) are respon-
sible for binding to c-Met [19^22]. Small molecule consists of
the N-terminal hairpin domain, K1, and K2 designated HGF/
NK2 exists as a naturally biosynthesized variant [23,24], and
importantly HGF/NK2 shows motogenic activity but lacks
mitogenic activity [19]. HGF/NK2 capable of receptor binding
is thus an antagonist for the mitogenic activity of HGF, yet
retains selective agonistic activity in the induction of cell mo-
bility. Lokker et al. subsequently demonstrated that HGF/
NK1 which consists of the N-terminal hairpin domain and
K1 and is smaller than HGF/NK2 which binds the c-Met/
HGF receptor and exerts motogenic activity at higher concen-
trations [28]. Like HGF/NK2, HGF/NK1 lacks mitogenic ac-
tivity, rather it antagonizes the mitogenic activity of HGF.
However, an HGF-antagonist which abrogates mitogenic,
motogenic, and morphogenic activities of HGF has heretofore
never been identi¢ed. In the present study, we developed
HGF/NK4 which consists of the N-terminal hairpin domain
and four kringle domains following limited digestion of HGF.
HGF/NK4 binds the c-Met/HGF receptor, but does not re-
tain mitogenic, motogenic, and morphogenic activities. Im-
portantly, HGF/NK4 antagonizes mitogenic, motogenic, mor-
phogenic, and tumor inhibitory activities of HGF.
HGF/NK2 binds the c-Met/HGF receptor and retains mo-
togenic activity. In contrast, HGF/NK4, which is larger than
HGF/NK2 and consists of HGF/NK2 plus K3 and K4, also
binds the c-Met/HGF receptor but does not induce cell scat-
tering. We speculate that K3 and K4 in HGF/NK4 do not
block the binding between HGF/NK2 and c-Met, but do sup-
press the scattering e¡ect of HGF/NK2. On the other hand,
using highly puri¢ed HGF/NK4, we obtained evidence that
HGF/NK4 competitively inhibits both the binding of HGF to
the receptor and HGF-induced tyrosine phosphorylation, but
importantly it has no HGF-related biological activities. Our
results raise a question on whether the entire K-chain of HGF
might retain similar antagonistic activity for biological activ-
ities of HGF. Previous reports showed that recombinant K-
chain binds to c-Met/HGF receptor and has no apparent mi-
togenic activity [18^21], but with regard to motogenic activity,
the reports are controversial. One group suggested that the K-
chain has a weak motogenic activity [19], but others found
that it did not have a weak motogenic activity [18,21]. How-
ever, these previous studies were done using crude or partially
puri¢ed preparation of the K-chain, and moreover, these stud-
ies neither examined multiple biological activities of the K-
chain at higher concentrations nor examined antagonistic ac-
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Fig. 6. Inhibitory e¡ect of HGF/NK4 on tyrosine autophosphoryla-
tion of the c-Met/HGF receptor induced by HGF. HGF (110 pM)
and/or HGF/NK4 were added to the cultures of A549 cells and cells
were extracted 10 min later. The c-Met/HGF receptor was immuno-
precipitated with anti-c-Met polyclonal antibody and immunoprecip-
itated materials were subjected to SDS-PAGE, under reducing con-
ditions. Proteins were electroblotted onto PVDF membrane and
probed with anti-c-Met polyclonal antibody or anti-phosphotyrosine
monoclonal antibody. IB, immunoblotting.
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tivity of the K-chain for HGF. Whether the K-chain has a
similar antagonistic activity as seen with HGF/NK4 remains
to be addressed.
Recently, the relationship between tumor invasion and stro-
mal-derived HGF have received much attention [12,13]. Most
carcinoma cells (tumor cells originating from epithelial tissues
and 90% of tumors are epithelial origin) express c-Met, and
overexpression of c-Met is often noted in more malignant
cancer cells [29^33]. HGF induces invasion of carcinoma cells
in vitro [12,13,34] and functional coupling between HGF and
Met enhances invasion and metastasis in certain tumor cells
[35]. Moreover, HGF may also be involved in neovasculariza-
tion in tumor tissues [14,15]. Based on all these observations,
HGF/NK4, an antagonist of HGF may have therapeutic po-
tential to prevent invasion and metastasis of various carcino-
ma cells. Ongoing studies have shown HGF/NK4 prevents
tumor invasion and metastasis in vivo as well as in vitro.
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